Physicians' Academy for Cardiovascular Education

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD

Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF

5' education - Jan. 14, 2020 - Akshay S. Desai, MD

LDL-c, atherosclerotic plaques and CV risk - what to do about it

10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD

Barriers to implementation of diabetes guidelines

5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit

GLP-1RA treatment effect in patients with T2DM and PAD

5' education - Jan. 8, 2019 - Prof. Subodh Verma, MD, PhD

Heart failure with mid-range ejection fraction

10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD

The burden of residual CV risk in the statin era

5' education - Jan. 6, 2020 - Erin Bohula, MD

Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial

5' education - Dec. 19, 2019 - Prof. David Morrow, MD

Three lines of evidence for triglycerides as a CV risk factor

10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg

PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF

10' education - Dec. 10, 2019 - Milton Packer, MD

Effect of BET inhibition on CV outcomes in ACS and diabetes patients

10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD

New tool can help identify FH patients

3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia

Improved health status with SGLT2-inhibitor in HFrEF

3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - AHA 2019, Philadelphia

A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial

3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia

Possible favorable effects of icosapent ethyl on plaque-parameters

3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia

Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE

3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia

Factor XIa antibody non-inferior to standard thromboprophylaxis after knee surgery

Literature - Jan. 21, 2020 - Weitz JI et al., - JAMA 2020

The FOXTROT trial demonstrated that osocimab, a factor XIa-inhibitor, was non-inferior to enoxaparin in the prevention of VTE up to 10-13 days after knee arthroplasty.

Down-titration of diuretics predicts achievement of target dose of ARNI in real-world HFrEF patients

Literature - Jan. 21, 2020 - Pharithi RB et al., - ESC Heart Fail. 2020.

Sacubitril-valsartan was well tolerated in stable HFrEF patients in a real-world population. Target dose was achieved in most patients and was linked to down-titration of diuretic dose.

Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia

10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD
Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Prof. Landmesser shows data that form the rationale behind new guideline recommendations, among which the lower LDL-c target for patients at very high risk.

Training for a first-time marathon has favorable effects on BP and aortic stiffness

Literature - Jan. 20, 2020 - Bhuva AN et al., - J Am Coll Cardiol. 2020

This prospective study showed that 6 months training and completion of a first-time marathon results in a reduction in blood pressure and aortic stiffness in healthy participants.

More insight into daily clinical practice and more collaboration needed to improve diabetes care

3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD
Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.

DIabetes summit Prof. Mathieu concludes that clinical practice lags behind regarding available evidence on management of T2DM. She considers what causes this gap and who needs to act to change it.

Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them

5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit
Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.

Diabetes summit Prof. Cosentino considers the how and why of development of clinical guidelines, in light of new recommendations in the 2019 ESC/EASD diabetes guidelines.

Early childhood and prepregnancy maternal weight related to weight at 15 years of age

Literature - Jan. 17, 2020 - Yoshida S et al., - Pediatr Obes. 2020

A longitudinal study in Japan revealed that being overweight/obese at age 3, or having had an overweight/obese mother before she was pregnant is predictive of overweight/obesity at 15 years in girls.

How can triglycerides increase CV risk?

10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD
How can high levels of triglyceride-rich lipoproteins lead to myocardial infarction? Prof. Nordestgaard gives a presentation on mechanisms by which triglycerides can lead to CV events.

How can high levels of triglyceride-rich lipoproteins lead to myocardial infarction? Prof. Nordestgaard gives a presentation on mechanisms by which triglycerides can lead to CV events.

Clinical phenotype-based HFpEF subgroups respond differently to aldosterone antagonist therapy

Literature - Jan. 15, 2020 - Cohen JB et al., - JACC Heart Fail. 2020

Three phenogroups were identified in TOPCAT HFpEF patients, ranging from a low-risk group with mild symptoms to a high-risk obese, diabetic group with advanced symptoms that responded well to spironolactone.

The growing global challenge of CV risk

5' education - Jan. 15, 2020 - Thomas Gaziano, MD
Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.

Thomas Gaziano presents data on worldwide trends in CV mortality and CV risk factors. He gives a brief update on different programs on CVD prevention, both in high and low income countries.

Effects of SGLT2 inhibitor on clinical outcomes in acute decompensated HF patients

Literature - Jan. 14, 2020 - Damman K et al., - Eur J Heart Fail. 2020

This pilot RCT in acute decompensated HF patients showed that empagliflozin did not result in reduction of primary endpoints, but did reduce a combined endpoint of worsening HF, rehospitalization for HF or death compared to placebo.

Phase III CV outcomes trial with fish oil in dyslipidemia patients discontinued

News - Jan. 14, 2020

The Phase III STRENGTH trial evaluating the effect of a fish oil-derived mixture of free fatty acids on CV outcomes in patients with mixed dyslipidemia and high CVD risk is closed due to a low likelihood to show benefit.

Agenda